Similar Articles |
|
The Motley Fool February 15, 2006 Stephen D. Simpson |
Good Marks for Caremark The pharmacy benefits management company should have even more positive operating leverage left in the tank. Investors, take note. |
The Motley Fool October 29, 2009 Brian Orelli |
Expressing Itself Nicely A nice quarter for Express Scripts. |
The Motley Fool October 27, 2005 Stephen D. Simpson |
Can ESRX Spell P-r-o-f-i-t-s? A company focused on lowering medical costs sounds like a good idea, but investors should dig deeper. While pharmaceutical benefits manager Express Scripts offers high growth and high valuation, it may also offer higher-than-average risk. |
The Motley Fool March 4, 2005 Tom Taulli |
In the Express Scripts Lane Express Scripts' strong results bring a much-needed lift to health-care investors. |
The Motley Fool August 31, 2011 Shubh Datta |
CVS Caremark Flattened by Higher Costs CVS Caremark profits remained relatively flat this quarter despite a substantial increase in revenue. |
The Motley Fool December 19, 2006 Matthew Crews |
Express Scripts' Takeover Battle The pharmacy benefits manager challenges CVS with a higher bid for rival Caremark RX. Investors, stay tuned -- this is far from over. |
The Motley Fool June 12, 2006 Brian Gorman |
Biogeneric Payoff? A new report indicates that spending on specialty drugs increased 17.5% in 2005. This growth bodes well for makers of biotech drugs, which make up a large portion of the specialty drug category. Investors, take note. |
The Motley Fool February 25, 2009 Brian Orelli |
The Best Kind of Generic Growth Pharmacy benefit managers profit from penny-pinchers. |
The Motley Fool July 30, 2009 Brian Orelli |
A Good Business Model for Bad Times Some businesses benefit when people are hurting. It's a beautiful time to be a pharmacy benefit manager, since that business model essentially results in them making more money when their customers save money. |
The Motley Fool August 1, 2008 Brian Orelli |
Express Scripts Gets More Generic Pharmacy benefits manager Express Scripts may not have grown the top line by much in the second quarter, but using more generic drugs had a positive effect on the bottom line. |
CFO March 1, 2012 David McCann |
Companies May Win This Drug War The conflict between Express Scripts and Walgreen just might lead to lower drug-benefit costs for companies. |
The Motley Fool July 27, 2004 Brian Gorman |
Medco's Pumped About Generics Generic drugs are actually helping improve Medco's margins, making it a winner with investors and health-care plans. |
The Motley Fool November 4, 2009 Brian Orelli |
This One Is Thriving in a Recession Saving customers money makes it easy for Medco. |
The Motley Fool July 25, 2011 Brian Orelli |
Express-Medco: Just What the Doctor Prescribed In perhaps the most obviously beneficial merger ever, Express Scripts announced its plan to buy Medco Health Solutions for $29.1 billion. |
The Motley Fool August 24, 2010 David Meier |
Can Express Scripts Produce Big Returns? Express Scripts generates incredible returns on equity. Let's see how they do it. |
The Motley Fool April 13, 2009 Brian Orelli |
Prescriptions for Acquisitions Express Scripts announces that it is buying WellPoint's NextRx pharmaceutical benefit management subsidiaries for almost $4.7 billion. |
The Motley Fool June 24, 2011 Shubh Datta |
A Big Question Looms for Walgreen Strong quarterly results enable the company to maintain its annual outlook, but a breakup costs dearly in the short term. |
Managed Care March 2006 |
Study: No Need To Burden Consumers To Cut Drug Bill A study by Express Scripts shows that changing the prescription benefit copayments can reduce costs by encouraging more use of generic drugs. All without shifting costs to consumers. |
The Motley Fool December 6, 2007 Selena Maranjian |
Your Drugs Are in the Mail Order medications online and save. According to a study by the Lewin Group, mail-order pharmacies, such as Medco and Express Scripts, can save you as much as 10% overall. |
The Motley Fool August 5, 2004 Tim Beyers |
Will Lawsuit Hurt Express Scripts? Although investors seem to be over the initial jitters arising from Express Scripts' problems, the stock is still down more than 12% since New York Attorney General Eliot Spitzer filed a lawsuit accusing the pharmacy benefits manager of fraud. |
CIO September 26, 2013 Stephanie Overby |
Big Data Project Cuts Prescription Costs Express Scripts analytics portal helps doctors prescribe more cost-effective medicines. |
The Motley Fool February 17, 2005 Stephen D. Simpson |
Caremark Hits the Mark Again With expectations of higher than 25% growth in 2005, the pharmacy benefits manager looks like it will continue to take care of its investors. |
The Motley Fool April 19, 2011 Bryan White |
Rising Star Buy: Medco Health Medco has a much brighter future than its current stock price implies. |
The Motley Fool April 29, 2010 Brian Orelli |
A Prescription to Investigate Further Let's not worry just yet about Medco's margins. |
The Motley Fool May 4, 2011 Jason Knapp |
Generic Drugs and Old People Could Make You Rich CVS hasn't generated market-beating returns yet -- but it will. |
The Motley Fool October 8, 2011 Shubh Datta |
Impasse Hurts Walgreen's Quarter Walgreen posted a staggering 69% earnings jump but still saw its shares slide. |
Managed Care September 2006 |
Payers, Consumers Benefit as Patents Expire The generic drug market seems ready to explode, according to reports from IMS Health and the Generic Pharmaceuticals Association. |
The Motley Fool November 9, 2005 Brian Gorman |
Caremark's Room to Grow Fickle investors may fret about near-term growth, but the pharmacy benefit manager is prepared for the long haul. Investors looking for a long-term holding may want to mark a place in their portfolio for this company. |
BusinessWeek May 9, 2005 Weintraub & Barrett |
BW 50: Can Caremark's Health Hold Up? Caremark Rx Inc. faces a growing set of legal and market challenges, but Its drug-benefit business is soaring, and its CEO remains upbeat about the future. |
The Motley Fool July 29, 2004 Brian Gorman |
Express Scripts' Bad Day Express Scripts joins other pharmacy benefit managers (PBM) embroiled in legal controversy. But the company, and its competitors, will eventually emerge from the fray and their stocks may then be worth another look. |
The Motley Fool May 30, 2011 Andrew Tonner |
Does UnitedHealth Group Deserve a Spot in Your Portfolio? Although UnitedHealth Group could look like a stock for your portfolio right now, the search doesn't end here. |
Managed Care September 2005 John Carroll |
Plans Struggle for Control of Specialty Pharma Costs Biotech drugs are a quickly growing component of health plan budgets. Here are the latest management techniques. |
Managed Care November 2005 |
Recently Introduced Generics Helped Pbm Control Its Costs The top five generic drugs released over the past three years reduced pharmacy spending by 4.8 percent largely due to the timing of the release of generic products to the market. |
The Motley Fool November 3, 2010 Brian Orelli |
A Generic Prescription for Double-Digit Growth MedcoHealth Solutions has it. |
Managed Care August 2007 |
Managed Care Outlook Specialty drugs increasingly used to treat chronic conditions. |
The Motley Fool February 16, 2005 Brian Gorman |
Medco's Double-Edged Sword The pharmacy benefit manager's latest financial report indicates that its business remains robust. But is it at the expense of retail pharmacies? |
Managed Care January 2005 |
Generic Prescription Fill Rates Vary Widely Across the Country Use of generic medications continues to increase, but the generic fill rate varies widely across the country, with possible explanations including variations in prescribing patterns, state regulations, etc. |
The Motley Fool February 2, 2007 Ryan Fuhrmann |
Uncertain Outlook on CVS Has the retail pharmacy bit off more than it can chew? Investors may soon look back longingly to the day when CVS focused as much on organic, or internal, means to grow its business as it does on acquisitions to buy outside market share. |
The Motley Fool June 30, 2011 David Williamson |
Pharmacy Benefits Delivering Drama CVS claims another Medco client and one messy split. |
The Motley Fool June 13, 2005 Brian Gorman |
Walgreen Strikes Back The traditional drugstore operator is expanding its mail-order business. This should be a welcome sign to investors. |
The Motley Fool January 3, 2012 Shubh Datta |
Things Aren't Looking Great For Walgreen Walgreen net income slips due to a meek flu season and its breakup with Express Scripts. |
The Motley Fool October 6, 2011 Dan Caplinger |
Has Medco Health Solutions Become the Perfect Stock? A lot has happened in the pharmacy benefits management space since we looked at Medco last year. |
The Motley Fool March 6, 2009 Brian Orelli |
Don't Let It Go! Health insurer WellPoint is trying to sell its pharmacy business management segment. Is it the right move for them for right now? |
The Motley Fool December 19, 2006 Brian Gorman |
Novartis Cuts in Line at the Drugstore Consolidation in pharmacy benefits management may leave Novartis most resistant to pricing pressure. Investors, take note. |
The Motley Fool March 22, 2010 Dave Mock |
A Big Upgrade for CVS Caremark This bullish call comes from more than just one analyst. |
Managed Care November 2007 Martin Sipkoff |
PBMs Agree to Disclose What They Pay for Drugs Pharmacy benefit managers will charge employers a straight administrative fee, rather than make much of their income through deals with the drug industry. |
The Motley Fool November 8, 2006 Michael P. Cecil |
CVS/Caremark: A Brobdingnagian Drug Seller The merger of CVS and Caremark says a lot about pharmaceutical retailers and pharmacy benefit mangers trying to deal with a rapidly changing paradigm. |
The Motley Fool July 26, 2010 Seth Jayson |
Show Me the Money, Walgreen All cash flow is not created equal. |
The Motley Fool April 30, 2008 Brian Orelli |
Medco's Far-From-Generic Quarter Pharmacy benefit manager Medco Health Solutions benefits from new generic drugs. |
The Motley Fool October 2, 2011 Shubh Datta |
Would You Invest in This Drug Retailer? Is CVS Caremark worth your investment? |